ABVD is a chemotherapy regimen used as the first line treatment for Hodgkin lymphoma, having replaced the older MOPP protocol. It combines four chemotherapy drugs given together: Adriamycin, also known as doxorubicin, bleomycin, vinblastine, and dacarbazine.
Facts
Origin YearThe initial results of ABVD were reported in an Italian thesis from the 1974-75 academic year at the University of Milan. This fact records 1975, the year Gianni Bonadonna's group published the results in English, the point the regimen entered the international literature. Connections
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundation
Wikidata: ABVD
Wikidata Q287631, class allow-list match (w-wdresolver-0926)View the Source ABVD (Wikipedia)
ABVD - Development section
The results were published in English in 1975 by an Italian group led by Gianni Bonadonna.
Lead section
It consists of concurrent treatment with the chemotherapy drugs: Adriamycin (also known as doxorubicin/hydroxydaunorubicin, designated as H in CHOP) Bleomycin Vinblastine Dacarbazine (similar to procarbazine, designated as P in MOPP and in COPP) == Medical uses == As of 2007, ABVD is widely used as the initial chemotherapy treatment for newly diagnosed Hodgkin lymphoma.
Treats: Hodgkin Lymphoma, Lead: treats Hodgkin Lymphoma
ABVD is a chemotherapy regimen used in the first-line treatment of Hodgkin lymphoma, replacing the older MOPP protocol.
View the SourceReader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.
View At A Past Year
Choose a year to see this entry's facts and connections as the atlas records them at that moment: what it held then, what it held instead, and what it had not yet adopted. Choose Present for the current record.